Home 
FOR AUTHORS Bratislava Medical Journal 2013 Bratislava Medical Journal Vol.114, No.5, p.262-268, 2013
FOR AUTHORS Bratislava Medical Journal 2013 Bratislava Medical Journal Vol.114, No.5, p.262-268, 2013
Journal info
|
||||
Select Journal
Journals
Bratislava Medical Journal 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 Endocrine Regulations General Physiology and Biophysics Neoplasma Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Bratislava Medical Journal Vol.114, No.5, p.262-268, 2013 |
||
| Title: Update on medical management of dyslipidemia and atherosclerosis | ||
| Author: E. Ginter, V. Simko | ||
| Abstract: Scientific achievements revealing the pathogenesis of atherosclerosis resulted in the second half of the 20th century in major improvement in prevention and therapy of cardiovascular disorders (CVD). Essential became the understanding of a critical pathogenetic role of the low-density lipoproteins (LDL), mainly their oxidized form (oxLDL) and also the protective potential of the high-density lipoproteins (HDL). CVD is now regarded to be an inflammatory disease in which a systemic inflammatory reaction is combined with an accumulation of immune cells in atherosclerotic plaques. Higher intake of antioxidants in fruit and vegetable, life style modifications, cessation of smoking, physical exercise and introduction of medications that lower LDL and promote HDL (statins, niacin and fibrates) resulted in a substantial decline of the killer effect of unmanaged CVD. In the United Kingdom the male CVD mortality declined between 1970 and 2009 from 700 to 200 deaths per 100,000. In France, CVD mortality in the middle age population (25–64 years) is now responsible for death in only 15 % men and in 11 % women. Unfortunately, in many parts of the world CVD mortality remains a prominent population scourge. Recent dicoveries, especially on the role of peroxisome proliferator-activated receptors (PPAR) and antisense compounds used in addition to established anti-atherogenic medications, promise further gains in the fight against atherosclerosis (Fig. 4, Ref. 54). |
||
| Keywords: cardiovascular disease, LDL, ox-LDL, HDL, statins, niacin, fibrates, peroxisome proliferator, antisense compounds. | ||
| Year: 2013, Volume: 114, Issue: 5 | Page From: 262, Page To: 268 | |
| doi:10.4149/BLL_2013_054 |
||
|
|
 download file |
|